Utility of the Neonatal Calf Model for Testing Vaccines and Intervention Strategies for Use against Human RSV Infection

• Published in: Vaccines (Basel) Vol. 7; no. 1; p. 7
• Main Authors: Guerra-Maupome, Mariana, Palmer, Mitchell V, McGill, Jodi L, Sacco, Randy E
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.01.2019; MDPI
• Subjects: Age; Antibodies; calf model; Calves; Cattle; Gene expression; Genomes; human; Infections; Kinases; Laboratory animals; Model testing; Neonates; Pathogenesis; Pediatrics; Pneumonia; Proteins; Respiratory diseases; Respiratory syncytial virus; Respiratory tract; Respiratory tract diseases; Review; RNA polymerase; RSV; therapeutics; Vaccines; Viruses; United States > US; therapeutics; RSV; vaccines; human; calf model
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines7010007

Respiratory syncytial virus (RSV) is a significant cause of pediatric respiratory tract infections. It is estimated that two-thirds of infants are infected with RSV during the first year of life and it is one of the leading causes of death in this age group worldwide. Similarly, bovine RSV is a primary viral pathogen in cases of pneumonia in young calves and plays a significant role in bovine respiratory disease complex. Importantly, naturally occurring infection of calves with bovine RSV shares many features in common with human RSV infection. Herein, we update our current understanding of RSV infection in cattle, with particular focus on similarities between the calf and human infection, and the recent reports in which the neonatal calf has been employed for the development and testing of vaccines and therapeutics which may be applied to hRSV infection in humans.